RPL17 and neoplasm: We deduced that it may be possible to reverse T cell dysfunction by intervention in these pathways to revive CD8+ T cells against tumor activity (such as TIGIT, TNFRSF9, CTLA-4, LAG3, PD-1), and this approach maybe represented new strategies for immunotherapy against LUAD.